Evidence map›Paper›PMID 41461402›Full record

ReviewCancer reports (Hoboken, N.J.)2026

Venetoclax-Based Therapy for Early Relapse in Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Minireview.

Yufeng Du, Mohammad Arian Hassani, Chunhong Li, Zhijia Zhao, Yikun Liu, Chengtao Zhang, Jinsong Yan

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yufeng DuDepartment of Hematology, Dalian Key Laboratory of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, The Second Hospital of Dalian Medical University, Dalian, China.ORCID 0000-0003-3159-9629
Mohammad Arian HassaniDepartment of Hematology, Dalian Key Laboratory of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, The Second Hospital of Dalian Medical University, Dalian, China.ORCID 0000-0003-0392-7947
Chunhong LiDepartment of Hematology, Dalian Key Laboratory of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, The Second Hospital of Dalian Medical University, Dalian, China.
Zhijia ZhaoDepartment of Hematology, Dalian Key Laboratory of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, The Second Hospital of Dalian Medical University, Dalian, China.ORCID 0009-0007-3337-8455
Yikun LiuSchool of Public Health, Dalian Medical University, Dalian, China.
Chengtao ZhangDepartment of Hematology, Dalian Key Laboratory of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, The Second Hospital of Dalian Medical University, Dalian, China.ORCID 0000-0002-9958-0839
Jinsong YanDepartment of Hematology, Dalian Key Laboratory of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, The Second Hospital of Dalian Medical University, Dalian, China.ORCID 0000-0003-4109-2602

Funding

Central Guidance on Local Science and Technology Development Fund of Liaoning Province 2023JH6/100100019
6 · The paper itself

Abstract

backgroundRefractory/relapsed acute myeloid leukemia (R/R-AML) typically exhibits resistance to conventional chemotherapy, resulting in a poor overall therapeutic outcome. Salvage allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the primary treatment option in such patients. However, posttransplant relapse is still a challenge, with no established effective regimens. CASE: In this case report, we present the case of a 40-year-old male diagnosed with R/R-AML who underwent salvage allo-HSCT. Unfortunately, after 4 months of follow-up, a relapse occurred. We modified the immunosuppressive therapy and administered donor lymphocyte infusion (DLI) and decitabine but failed to obtain complete remission (CR). Subsequently, a combination of venetoclax (Ven) and azacitidine (Aza), followed by the DLI regimen, was initiated. The patient achieved CR with no measurable residual disease.

conclusionOur data suggest that the administration of Ven in combination with Aza followed by the DLI regimen used for early post-HSCT relapsed AML could serve as a valuable reference for treating similar patients.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteNeoplasm Recurrence, LocalSulfonamidesAdultAzacitidineHumansLymphocyte TransfusionMaleRemission InductionSalvage TherapyTransplantation, HomologousTreatment OutcomeAzacitidineBridged Bicyclo Compounds, HeterocyclicSulfonamidesvenetoclaxacute myeloid leukemiaallogeneic hematopoietic stem cell transplantationazacitidinedonor lymphocyte infusionrefractory/relapsedvenetoclax

Identifiers

PMID41461402
PMCPMC12747801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.